This suggests that a correct dosage of HPF1 is important for proper balancing of various PARP1- and PARP2-catalysed reactions, and therefore subtler changes beyond simple loss-of-function might also be of therapeutic relevance in both cancer and other diseases. The gene discussed is PARP2; the disease is cancer.